{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:46:35Z","timestamp":1785750395288,"version":"3.56.0"},"reference-count":0,"publisher":"Opast Group LLC","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Immunol"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the most common progressive and irreversible neurodegenerative disorder in humans that\naffects memory, thinking and behavior. Impairment in synaptic plasticity is one of the hallmarks in AD, with most of\nthe impairment occurring in the hippocampal region, a key part of the brain for memory and learning. Therefore,\nthe upregulation of hippocampal plasticity is critical to remediate the progression of AD and preserve memory\nformation and cognitive functions. Recent studies have described \u03b2-hydroxy-\u03b2-methylbutyrate (HMB), a body building\nsupplement commonly used by athletes, as a candidate molecule for improving hippocampal plasticity. Clinically, AD\nis characterized by the abnormal accumulation of beta amyloid (A\u03b2) plaques, coupled with intracellular aggregates of\nhyperphosphorylated tau protein. In addition to enhancing hippocampal plasticity, HMB has been also demonstrated\nto lower amyloid plaques in a mouse model of AD. Although liver is rich in peroxisome proliferator-activated receptor\nalpha (PPAR\u03b1), recent findings have established the presence of PPAR\u03b1 in hippocampus and other parts of the brain.\nInterestingly, HMB has been shown to utilize PPAR\u03b1 for lowering plaques and increasing hippocampal plasticity. Here,\nwe discuss these newly described features of HMB with possible implications for the use of HMB supplement in patients\nwith dementia and AD.<\/jats:p>","DOI":"10.33140\/jcei.11.03.01","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:51:49Z","timestamp":1784292709000},"page":"01-08","source":"Crossref","is-referenced-by-count":0,"title":["Prospect of Muscle-Building Supplement HMB in Alzheimer\u2019s Disease"],"prefix":"10.33140","volume":"11","author":[{"given":"Abhiram","family":"Uppalapati","sequence":"first","affiliation":[{"name":"Department of Neurological Sciences, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahiri","family":"Vishnubhotla","sequence":"additional","affiliation":[{"name":"Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6048-9598","authenticated-orcid":false,"given":"Kalipada","family":"Pahan","sequence":"additional","affiliation":[{"name":"Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18493","published-online":{"date-parts":[[2026,7,13]]},"container-title":["Journal of Clinical &amp; Experimental Immunology"],"original-title":["Prospect of Muscle-Building Supplement HMB in Alzheimer\u2019s Disease"],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:04:49Z","timestamp":1785747889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.opastpublishers.com\/open-access-articles\/prospect-of-musclebuilding-supplement-hmb-in-alzheimers-disease-10986.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":0,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,7,13]]}},"URL":"https:\/\/doi.org\/10.33140\/jcei.11.03.01","relation":{},"ISSN":["2475-6296"],"issn-type":[{"value":"2475-6296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}